Topics
late
AI
Amazon
Image Credits:Alessandro Di Ciommo/NurPhoto(opens in a new window)/ Getty Images
Apps
Biotech & Health
mood
Image Credits:Alessandro Di Ciommo/NurPhoto(opens in a new window)/ Getty Images
Cloud Computing
Commerce
Crypto
Enterprise
EVs
Fintech
Fundraising
convenience
Gaming
Government & Policy
ironware
layoff
Media & Entertainment
Meta
Microsoft
Privacy
Robotics
surety
Social
Space
startup
TikTok
Transportation
Venture
More from TechCrunch
issue
Startup Battlefield
StrictlyVC
Podcasts
Videos
Partner Content
TechCrunch Brand Studio
Crunchboard
adjoin Us
SoftBank Group founder Masayoshi Sonannounced on Thursdaythat the Nipponese tech giant star has set up a joint venture in the country with Chicago - base health technical school companyTempus . Together , the pair be after to develop AI - powered personalize medical services , by room of analyzing data in Japan under the name SB Tempus .
The company plans to come out with oncology . Cancer remains the big cause of death in Japan , according to Son , whose father passed away last year because of the disease .
This move underscores Son ’s challenging , wider focus on AI . Today , during the ad hoc press league , he filled out some details around a more specific practical app within that : the medical diligence .
SoftBank ’s tie with Tempus precede today ’s JV news . It invested $ 200 million in Tempus in April , good beforeTempus ’s Nasdaq first appearance in the first place this month . Tempus , once valued at $ 8.1 billion in 2022 , raisednearly $ 411 millionat a valuation of more than $ 6 billion via its IPO . Its evaluation , however , has not stood up : its mart detonating machine currently is$4.5 billion .
The U.S.-based genomic examination and data psychoanalysis company was start by successive entrepreneur and billionaire Groupon founder Eric Lefkofsky in 2015 after noticing that doctors did n’t rely on information during his wife ’s treatment of breast Cancer the Crab .
Tempus competes with manufacture peer including Foundation Medicine , which uses big data to analyse tumour , and Guardant Health , a biotech company that sell blood tests to track and potentially detect cancer .
SB Tempus will be a vehicle for Tempus to land its data point - drive medical technology to Japan . Tempus will “ build clinical sequencing potentiality , engineer patient data and build a real - human beings datum business in Japan , ” and Son said SB Tempus would provide genomic testing , medical data accumulation and depth psychology ( genomic , clinical , pathology and imaging data ) , as well as AI insights for personalized treatments and therapies .
Join us at TechCrunch Sessions: AI
Exhibit at TechCrunch Sessions: AI
Both fellowship have made a satisfying investment funds in this speculation . SoftBank and Tempus , severally , hold a 50 % stakes , with SoftBank set to inject 30 billion yen , tantamount to around $ 188 million , Son said on the stage at the medium briefing .
SB Tempus , which will start surgical process in August , will volunteer three aesculapian overhaul to hospital using AI to analyse personal medical data point as early as within the class , according to Son .
How it works : The JV company will begin collecting and analyzing patient genetic information from Japanese hospitals and university . The data , which will include genomic , pathologic , clinical information and picture images , will be used to train AI patterns for patients in Japan . The company will ply infirmary with processed datum for clinical use , and the AI offerings will suggest the best intervention for patients .
Son stated that in Japan , only about 1 % of patient role have experience with genomic testing . In comparison , roughly 30 % have had the prospect to receive genomic testing in the U.S. He also mentioned the company ’s destination of reaching the same stage as the U.S.
As well as fighting cancer , the program is to expand to other disease , such as physiological psychology , radiology and cardiology .
The annunciation come about a week after the Japanese technical school giant star ’s chief executive officer made a particular public appearance last Friday at the group ’s yearly meeting .
Son said AI will be 10,000 times sassy than mankind in a decade and position out his vision for a worldly concern feature Artificial Super Intelligence ( ASI ) at the meeting . He also advert that SoftBank ’s past investment were “ just a warm - up ” for his dream to make an epoch of AI .
Son reiterated how AI will benefit humans in various sector , adding that medicine is one example . SoftBank is reportedly one of the companies interested in invest in Perplexity AI , the U.S.-based AI company , at a rating of $ 3 billion , per Bloomberg ’s report today . TechCrunch was the first to report on that roundback in April . )
A string of losses at SoftBank ’s investment arm Vision Fund led the Japanese technical school mogul to switch into “ defence style , ” take a more conservative investiture scheme . Now it really seems that SoftBank , which has billions of dollars in its war chest , is ready to mold in full swing to invest in AI .
